MYLAN LABORATORIES.(Brief Article)

Chemical Market Reporter,  June, 2000  

• E-mail
• Print
• Link

MYLAN LABORATORIES, a generics and branded pharmaceutical company, expects its earnings per share for the first quarter, which ended June 30, to be in a range of 14c. to 17c., below the 25c. per share earned during the same period last year and below analysts' projections of 31c. per share. The company cites several factors, including pricing pressures on major products, such as the anti-seizure medicine lorazepam and the anxiety treatment clorazepate.

Mylan also says sales by its ...

Read the rest of this article with a Free Trial at HighBeam Research.